Merck Wins Retrial In First Vioxx Federal Case
This article was originally published in The Pink Sheet Daily
A New Orleans federal jury found in favor of Merck Feb. 17 in a retrial of the firm's first federal Vioxx case
You may also be interested in...
A Houston jury was unable to reach a verdict in the first federal product liability trial over the COX-2 inhibitor.
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
With an unrestricted label and once-daily dosing, rivaroxaban will do battle with Boehringer-Ingelheim's dabigatran, which is dosed twice a day but can claim superior efficacy to warfarin in the atrial fibrillation population.